Actively Recruiting
Study of Peptide Receptor Radionuclide Therapy PRRT in Adults with Gastroenteropancreatic Neuroendocrine Tumors
Led by Methodist Health System · Updated on 2026-03-20
50
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the characteristics, treatment responses, survival outcomes, and side effects of Peptide Receptor Radionuclide Therapy PRRT in patients with gastroenteropancreatic primary neuroendocrine tumors NETs. This observational study aims to gather detailed clinical data to better understand how this therapy works for advanced NETs, especially given the significant number of patients presenting with or developing metastatic disease. The study involves patients treated with PRRT as decided by their doctors, focusing on those with metastatic or locally advanced, inoperable tumors that have shown disease progression despite prior therapy. Treatment details include molecular therapy using radioisotopes targeting NETs, with data collected over a seven-year period to evaluate tumor responses, survival, imaging findings, biomarkers, and adverse events. Participants will have their demographics, tumor specifics, biomarker levels, imaging results, survival rates, time to progression, treatment responses, disease progression, and side effects tracked for seven years from the date of their procedure. The study requires patients to consent and comply with study protocols, including signing informed consent in English, and aims to provide comprehensive long-term monitoring of the effects and outcomes related to PRRT treatment.
CONDITIONS
Brief Title
Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors
Research Team
C
Colette N Ndjom, MS
J
Jennifer Kirchner
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here